Review top news and interview highlights from the week ending December 8, 2023.
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The decision was supported by efficacy data from 36 patients from the ongoing phase 1/2 HGB-206 trial (NCT02140554) and 2 patients in the phase 3 HGB-210 trial (NCT04293185).
The FDA’s decision was based on data from the CLIMB-121 and CLIMB-131 clinical trials, and the decision makes it the first CRISPR-based gene therapy to be approved in the US.
The president and head of R&D at Taysha Gene Therapies discussed the early clinical evaluation of TSHA-102.
The cell therapy yielded a median overall survival of around 17 months compared with a historical overall survival of less than 12 months.
Benetic anticipates an announcement of interim results sometime around the midpoint of 2024.